• Skip to main content

Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

Early Phase 1

SRC Inhibition as a Potential Target for Parkinson’s Disease Psychosis

August 13, 2019

https://clinicaltrials.gov/ct2/show/NCT03661125?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F30%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
SRC Inhibition as a Potential Target for Parkinson’s Disease Psychosis

DESCRIPTION:
Condition:   Parkinson Disease Psychosis
Interventions:   Drug: Saracatinib;   Drug: Placebo Oral Tablet
Sponsors:   King’s College London;   AstraZeneca;   King’s College Hospital NHS Trust
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03661125

FIRST POSTED:
Fri, 07 Sep 2018 12:00:00 EDT

LAST UPDATE POSTED:
08/13/19 06:58AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03661125?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F30%2F2019&lupd_d=14&sort=nwst

Powered by Urgent Research

Copyright © 2025 Urgent Research